Key result
Daraxonrasib is linked to nonbacterial thrombotic endocarditis with severe mitral regurgitation and recurrent thrombosis.
Why the study?
Nonbacterial thrombotic endocarditis is a rare malignancy-associated condition causing systemic embolization and valvular dysfunction, and its presentation as new severe mitral regurgitation may be difficult to recognize.
Case Report (n=1)
Nonbacterial thrombotic endocarditis should be considered in oncology patients presenting with new subacute mitral regurgitation and thromboembolic events with negative blood cultures, potentially associated with KRAS inhibitor therapy.
Answers are grounded in this paper and cite their sources.
New dyspnea in KRAS inhibitor recipients warrants echocardiography to exclude NBTE; leaves open a potential drug association.
BACKGROUND: Nonbacterial thrombotic endocarditis (NBTE) is a rare malignancy-associated condition causing systemic embolization and valvular dysfunction. Its presentation as new severe mitral regurgitation (MR) may be difficult to recognize. CASE SUMMARY: A 76-year-old man with metastatic pancreatic adenocarcinoma developed progressive dyspnea after treatment with the KRAS inhibitor daraxonrasib. Echocardiography demonstrated new severe MR with leaflet thickening and broad-based echodensities. His course was complicated by pulmonary embolism, recurrent coronary thrombosis, and persistently negative blood cultures. Transesophageal echocardiography confirmed bilateral leaflet involvement with a central coaptation defect. Anticoagulation was changed to low-molecular-weight heparin. DISCUSSION: NBTE should be considered in patients with malignancy presenting with new MR and thrombotic events without evidence of infection. The temporal association with KRAS inhibition is noteworthy but does not establish causality. TAKE-HOME MESSAGE: NBTE may present as subacute MR. Echocardiography and clinical context are essential for timely diagnosis and management.
No takes yet. Share an insight, caveat, or question.
Etchegoyen et al. (2026) conducted a case report in Nonbacterial thrombotic endocarditis (NBTE) and severe mitral regurgitation in metastatic pancreatic adenocarcinoma (n=1). Daraxonrasib (KRAS inhibitor) exposure followed by anticoagulation with low-molecular-weight heparin was evaluated on Development of nonbacterial thrombotic endocarditis, new severe mitral regurgitation, pulmonary embolism, and recurrent coronary thrombosis. Daraxonrasib exposure in a 76-year-old man (n=1) with pancreatic cancer preceded nonbacterial thrombotic endocarditis with new severe mitral regurgitation and recurrent thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: